Lichen Planus

Rajani Katta

Lichen planus is an inflammatory mucocutaneous condition with characteristic violaceous polygonal flat-topped papules and plaques. Pruritus is often severe. Skin lesions may be disfiguring, and involvement of the oral mucosa or genital mucosa in severe cases may be debilitating. Oral lichen planus may predispose to the development of squamous cell carcinoma within lesions. Involvement of the scalp and the nails may also occur. While most cases of lichen planus are idiopathic, some may be caused by the ingestion of certain medications (e.g., gold, antimalarial agents, penicillamine, thiazide diuretics, beta blockers, nonsteroidal anti-inflammatory drugs, quinidine and angiotensin-converting enzyme inhibitors) or linked to hepatitis C virus infection. Patients with localized lichen planus are usually treated with potent topical steroids, while systemic steroids are used to treat patients with generalized lichen planus. (Am Fam Physician 2000;61:3319-24,3327-8.)

Lichen planus is an inflammatory mucocutaneous condition that usually exhibits a distinctive morphology. The prevalence of lichen planus is unknown, but it is estimated to occur in less than 1 percent of the population. Estimates of the prevalence vary among different populations, but the condition does not appear to exhibit a racial predilection. It most commonly affects middle-aged adults of both sexes, with a slight predominance in women.(1)

Clinical Presentation

The classic appearance of skin lesions includes violaceous polygonal flat-topped papules and plaques (Figure 1). Close examination reveals a reticulated pattern of white scale known as Wickham’s striae (Figure 2). Early cutaneous lesions may be difficult to diagnose, often appearing as scattered erythematous papules (Figure 3). More developed and extensive lesions may mimic discoid lupus, psoriasis or secondary syphilis. The flexor surfaces of the extremities, particularly the wrists, are common locations for lichen planus.

Another clue to the diagnosis is that lesions may occur in areas exposed to trauma, such as lacerations. This tendency is known as an isomorphic response, or Koebner’s phenomenon. Lesions often resolve with intense hyperpigmentation. Some physicians describe lichen planus with the six “Ps”: pruritic, polygonal, planar (flat-topped), purple papules and plaques. While some patients may be asymptomatic, most experience intense pruritus, a hallmark of lichen planus.

While this “classic” form of cutaneous lichen planus is the most common, other variants do exist and exhibit various morphologies. Patients with hypertrophic lichen planus present with thick hyperkeratotic plaques, commonly found on the anterior surface of the legs (Figure 4). In vesiculobullous lichen planus, patients exhibit blisters within the plaques, while the actinic type of lichen planus occurs on sun-exposed areas of skin.

While lichen planus often occurs only on cutaneous surfaces, it may also involve the oral mucosa, the genital mucosa, the nails and the scalp. Moreover, these areas may be exclusively involved. Oral lichen planus classically presents on the buccal mucosa as a white, lacy, reticular pattern (Figure 5). Papular, atrophic or erosive lesions may also occur. Erosive lesions, in particular, may be quite painful and lead to multiple complications such as secondary infections (particularly candida), and poor nutrition and dehydration secondary to pain. Patients with long-term oral mucosal lesions have an increased risk of developing squamous cell carcinoma within the lesions.(2) Patients with these lesions should undergo regular oral follow-up, and a biopsy of any suspicious lesions should be performed.

Genital lichen planus may also exhibit various morphologies. In men, the classic lesion is visible as violaceous papules on the glans penis. In women, violaceous papules, hypertrophic lesions or erosions may occur, typically on the vulva. Erosive lichen planus may be very painful, and in longstanding cases, may lead to alterations of the genital architecture.(3) Squamous cell carcinoma has been reported in patients with genital lichen planus; therefore, follow-up and biopsy of any suspicious lesions are necessary.

Lichen planus may also involve the nails and the scalp. Multiple types of nail changes may occur that include ridging, distal splitting, thinning, subungual hyperkeratosis, pterygium formation and even loss of the nail.(1,4) However, none of these findings are specific to lichen planus. Additionally, lichen planus of the nails is often resistant to treatment. Lichen planus lesions that appear on the scalp are known as lichen planopilaris. Patients usually present with the initial clinical sign of areas of hair loss with keratotic follicular papules (Figure 6). If left untreated, these areas progress to scarring alopecia. The hair follicles are destroyed and regrowth of hair will not occur.


A diagnosis of lichen planus is reached on the basis of the typical clinical appearance and a punch biopsy of the lesion. Histopathology reveals characteristic findings of a band-like infiltrate of lymphocytes at the epidermal-dermal junction and damage to the basal cell layer. Epidermal changes include wedge-shaped hypergranulosis and irregular acanthosis leading to a saw-toothed appearance.(5)


The etiology of lichen planus is unknown, although many studies have investigated and support an immunologic pathogenesis. Lymphocytes, particularly T-cells, play a major role.(1,4,6) Other factors include antigen-presenting cells, adhesion molecules and inflammatory cytokines. While most cases of lichen planus are idiopathic, some are linked to medication use or hepatitis C virus (HCV) infection.

Lichenoid drug eruptions are reactions that may occur after exposure to various medications. These eruptions may exhibit a cutaneous and histologic appearance identical to that of idiopathic lichen planus and, thus, must be considered in every patient with lichen planus. While an exhaustive list of possible offending agents is quite long, the most common include gold, antimalarial agents, penicillamine, thiazide diuretics, beta blockers,(7) nonsteroidal anti-inflammatory drugs, quinidine and angiotensin-converting enzyme inhibitors.(8)

The interval between administration of the offending medication and the development of the lichenoid drug eruptions is usually a few months, although it may range from 10 days to several years.(8) While the eruptions spontaneously clear anywhere from weeks to months after discontinuation of the medication in many patients, some patients require systemic therapy. Unfortunately, no test is available to confirm the causality of a particular medication. If the patient is taking a potentially offending medication, it should be discontinued whenever possible.

In the past few years, lichen planus has been linked to HCV infection , with studies demonstrating a higher prevalence of anti-HCV antibody titers in patients with cutaneous and oral lichen planus, compared with control subjects.(9-14) The reported rates of association have differed widely, probably because of varying study design, oral versus cutaneous lichen planus and geography.

One study(12) reported that, in Indianapolis, a region with a low endemic prevalence of HCV, tests for HCV antibody were positive in 3.5 percent of patients with lichen planus. However, only patients with abnormal liver function tests were screened. Two studies of patients with lichen planus that did not exclude patients with normal liver function reported a positive HCV antibody in 23 percent of patients tested in Miami13 and 60 percent of patients tested in a region of Japan with a high endemic HCV prevalence.(14)

Although the manner in which HCV infection predisposes patients to the development of lichen planus is unknown, some speculate that long-term infection may lead to an aberrant immunologic response.(9) Considering the current evidence, it is appropriate to screen all patients with lichen planus for HCV infection.


The treatment of patients with lichen planus must be individualized (Table 1).(1,4,15-17) Patients vary greatly in severity of symptoms, extent of lesion involvement and response to treatment. Many treatment options are discussed in the literature, each with its own risk profile. Unfortunately, larger randomized trials to support the effectiveness of most of these treatments are lacking, and many treatments are recommended based on anecdotal evidence. Another factor to consider when treating patients with cutaneous lichen planus is that spontaneous remissions occur in the majority of patients after one year.(18)

Potent topical corticosteroids are used to treat the early or localized lesions of patients with cutaneous lichen planus. These ointments or creams are applied to the affected areas twice daily, with an initial trial treatment period of two to three weeks to monitor efficacy. Occlusion may be used to enhance the effect of the topical medication. For resistant or hyperkeratotic plaques, intralesional injections of triamcinolone acetonide (Kenalog) may be used.(1,15)

Oral corticosteroids are the most common treatment for patients with generalized cutaneous lichen planus,15,16 although recommendations concerning dosage and duration of therapy vary. The recommended prednisone dosage is 30 to 60 mg once daily for four to six weeks, with the dosage then tapered over the following four- to six-week period.(4) Other studies suggest treating patients at lower doses of prednisone or with other forms of corticosteroids, including short courses of oral prednisolone(16) or intravenous methylprednisolone.(15) While systemic corticosteroids alleviate symptoms in most patients, it is unclear whether this therapy affects the total duration of the disease.(4,15)

If corticosteroid resistance occurs, other treatment options are available. One controlled trial(15) demonstrated efficacy of treatment with a dosage of 30 mg daily of acitretin (Soriatane) once daily for eight weeks. When prescribing any retinoid, however, physicians must be familiar with the risk profile because of the severe teratogenicity associated with this class of drugs. Phototherapy using psoralens (PUVA) has also been reported to be effective in corticosteroid resistance. Although the duration of treatment is determined by patient response, good results have been reported after eight weeks of treatment. Multiple other therapies, such as griseofulvin (Grisactin), cyclosporine (Seromycin), dapsone and hydroxychloroquine (Plaquenil), have been anecdotally reported as effective for the treatment of patients whose lichen planus is corticosteroid-resistant.(4,15)

A topical corticosteroid is considered first-line therapy for patients with oral lichen planus.(15) One controlled Trial(17) demonstrated the effectiveness of fluocinonide (Lidex) ointment applied to dried oral mucosa six times daily for nine weeks. The steroid, in an adhesive base, was prepared by the pharmacy, although Orabase has also been recommended as an occlusive vehicle.(4) Other topical medications and systemic therapies have been used to treat patients with oral lichen planus15 that is corticosteroid-resistant. These therapies include topical cyclosporine, systemic corticosteroids, topical and systemic retinoids and oral PUVA.

RAJANI KATTA, M.D., is assistant professor of dermatology at Baylor College of Medicine, Houston, Tex. She earned her medical degree at Baylor College of Medicine and completed a residency in dermatology at Northwestern University Medical School in Chicago.

Address correspondence to Rajani Katta, M.D., Baylor College of Medicine, 6560 Fannin, Suite 802, Houston, TX 77030. Reprints are not available from the author.


(1.) Boyd AS, Neldner KH. Lichen planus. J Am Acad Dermatol 1991;25:593-619.

(2.) Silverman S, Gorsky M, Lozada-Nur F. A prospective follow-up study of 570 patients with oral lichen planus: persistence, remission, and malignant association. Oral Surg Oral Med Oral Pathol 1985;60:30-4.

(3.) Lewis FM. Vulval lichen planus. Br J Dermatol 1998;138:569-75.

(4.) Freedberg IM, Fitzpatrick, TB. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill, Health Professions Division, 1999. Variant Title: Dermatology in general medicine 2 v. (xxxi, 3002, 127 p.): ill.

(5.) Lever WF. Histopathology of the skin. In Elder, David E. Lever’s histopathology of the skin. 8th ed. Elder D, ed-in-chief; Elenitsas R, Jaworsky C, Johnson B, Jr, eds. Philadelphia: Lippincott-Raven, 1997. Variant Title: Histopathology of the skin (xvii, 1073 p., [14] p. of plates): ill.

(6.) Porter SR, Kirby A, Olsen I, Barrett W. Immunologic aspects of dermal and oral lichen planus: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83:358-66.

(7.) Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993;29:249-55.

(8.) Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998;16:325-32.

(9.) Sanchez-Perez J, De Castro M, Buezo GF, Fernandez-Herrera J, Borque MJ, Garcia-Diez A. Lichen planus and hepatitis C virus: prevalence and clinical presentation of patients with lichen planus and hepatitis C virus infection. Br J Dermatol 1996; 134:715-9.

(10.) Imhof M, Popal H, Lee JH, Zeuzem S, Milbradt R. Prevalence of hepatitis C virus antibodies and evaluation of hepatitis C virus genotypes in patients with lichen planus. Dermatology 1997;195:1-5.

(11.) Mignogna MD, Lo Muzio L, Favia G, Mignogna RE, Carbone R, Bucci E. Oral lichen planus and HCV infection: a clinical evaluation of 263 cases. Int J Dermatol 1998;37:575-8.

(12.) Chuang TY, Stitle L, Brashear R, Lewis C. Hepatitis C virus and lichen planus: A case-control study of 340 patients. J Am Acad Dermatol 1999;41:787-9.

(13.) Bellman B, Reddy RK, Falanga V. Lichen planus associated with hepatitis C [Letter]. Lancet 1995;346:1234.

(14.) Nagao Y, Sata M, Tanikawa K, Itoh K, Kameyama T. Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. Eur J Clin Invest 1995;25:910-4.

(15.) Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998;134:1521-30.

(16.) Kellett JK, Ead RD. Treatment of lichen planus with a short course of oral prednisolone [Letter]. Br J Dermatol 1990;123:550-1.

(17.) Voute AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus. A double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol 1993;75:181-5.

(18.) Irvine C, Irvine F, Champion RH. Long-term follow-up of lichen planus. Acta Derm Venereol 1991; 71:242-4.


Treatment of Lichen Planus

Treatment Indication Instructions

Potent topical Localized Apply a thin layer

corticosteroid creams cutaneous to involved areas

or ointments: clobetasol twice daily, for

(Temovate), halobetasol an initial trial of

(Ultravate), augmented 2 to 3 weeks;

betamethasone occlusion may be

diproprionate (Diprolene), used to enhance

diflorasone (Psorcon)(1,15) effects[*]

Systemic Generalized Oral prednisone, 30

corticosteroids(1,4,15,16) cutaneous to 60 mg, once

daily for 4 to 6

weeks, then taper

over next 4- to 6-

week period; lower

doses and other

types of


have been used

Acitretin (Soriatane)(15) Generalized 30 mg taken orally

cutaneous; once daily for

resistant to 8 weeks


PUVA (psoralen plus Generalized Administered 3

UVA phototherapy)(15) cutaneous; times weekly;

resistant to duration of

corticosteroids treatment based

on response; good

results reported

with 8 weeks of


Topical corticosteroids Oral Apply to dried oral

in alternative vehicle mucosa 6 times

(i.e., fluocinonide daily; taper use

[Lidex] ointment, as patient

0.05% in Orabase)(4,17) improves

Intralesional Hyperkeratotic Intralesional

triamcinolone or resistant injection of

acetonide (Kenalog)(1,15) localized 5 to 10 mg per

plaques mL into plaque

Treatment Efficacy Advantages

Potent topical Widely used, When used

corticosteroid creams although no appropriately,

or ointments: clobetasol controlled study no systemic

(Temovate), halobetasol has proved side effects

(Ultravate), augmented efficacy


diproprionate (Diprolene),

diflorasone (Psorcon)(1,15)

Systemic Widely used and Quick and often

corticosteroids(1,4,15,16) alleviates dramatic relief

symptoms in of symptoms

most patients,

but unclear if

total duration

of disease

is affected

Acitretin (Soriatane)(15) Efficacy Effective oral

demonstrated therapy of

by controlled relatively brief

trial duration

PUVA (psoralen plus Efficacy not Limited systemic

UVA phototherapy)(15) demonstrated side effects

by controlled

trial, but open

studies report

good results

Topical corticosteroids Efficacy When used

in alternative vehicle demonstrated appropriately,

(i.e., fluocinonide in controlled no systemic

[Lidex] ointment, trial of 9 weeks’ side effects

0.05% in Orabase)(4,17) duration

Intralesional Anecdotal When used

triamcinolone evidence appropriately,

acetonide (Kenalog)(1,15) no systemic

side effects

Treatment Disadvantages

Potent topical Use of topical corticosteroids

corticosteroid creams may be cumbersome for

or ointments: clobetasol some patients; use of lesser

(Temovate), halobetasol potency steroids is required

(Ultravate), augmented (hydrocortisone, 2.5%) on

betamethasone the face, axillae, groin or

diproprionate (Diprolene), genitals; higher potency

diflorasone (Psorcon)(1,15) steroids may rarely be used

(with caution) in these

locations for severe disease[*]

Systemic Many possible side effects

corticosteroids(1,4,15,16) that include effects on

blood pressure, blood

glucose and bone density

Acitretin (Soriatane)(15) Physician must be experienced

in prescribing retinoids;

severe risk of teratogenicity

and other possible systemic

side effects (e.g.,

hepatotoxicity, increase in

triglycerides); regular

laboratory monitoring


PUVA (psoralen plus Oral psoralens may induce

UVA phototherapy)(15) nausea; PUVA therapy

increases risk of skin cancer;

patient must travel to

phototherapy center for

each treatment

Topical corticosteroids Use of topical corticosteroids

in alternative vehicle may be cumbersome for

(i.e., fluocinonide some patients

[Lidex] ointment,

0.05% in Orabase)(4,17)

Intralesional Local atrophy, useful only for

triamcinolone localized lesions

acetonide (Kenalog)(1,15)

[*]–Use of any potent topical corticosteroid on extensive surface areas

for more than two weeks or under occlusion increases risk of atrophy,

striae, and systemic absorption.

Information from references 1, 4 and 15 through 17.

COPYRIGHT 2000 American Academy of Family Physicians

COPYRIGHT 2000 Gale Group